EGFR and lung adenocarcinoma: Additionally, the histone deacetylase inhibitor vorinostat can promote ferroptosis in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR)-mutant lung adenocarcinoma cells by suppressing the expression of solute carrier family 7 member 11 (SLC7A11) and improving the efficacy of ferroptosis inducers [59].